Xylazine, a powerful veterinary sedative and α₂-adrenergic agonist, is making headlines not for its legitimate uses, but for its rise as a dangerous street drug. Sold under brand names like Rompun (Bayer), Anased, and Sedazine, this clonidine analog has shifted from animal care to a public health threat in regions like the United States.

Xylazine in Veterinary Medicine: Legitimate Uses

As a core veterinary drug, xylazine is critical for:

• Sedating large mammals (horses, cattle) during procedures
• Inducing muscle relaxation and analgesia (pain relief)
• Combining with anesthetics for surgical care in animals

Veterinarians rely on it for its fast-acting calming effects, though dosage and interactions vary by species.

The Rise of “Tranq”: Xylazine Abuse in Humans

Xylazine (street name: “Tranq”) is now a widespread illicit drug—often cut with fentanyl, heroin, or cocaine. Key dangers of human xylazine use include:

• Non-opioid overdose risk: Naloxone (opioid reversal) does not counter xylazine’s effects.
• Skin necrosis: Slow-healing, painful wounds (a signature of “tranq” abuse).
• Severe sedation: Can lead to unconsciousness, respiratory distress, or coma.

Xylazine’s History: From Antihypertensive to Street Drug

First studied as a human antihypertensive (blood pressure medication), xylazine was abandoned for human use and marketed as a veterinary sedative. Its mechanism (α₂-receptor activation) was uncovered in 1981, spurring development of similar drugs like medetomidine.

Why Xylazine Matters Now

Public health agencies are prioritizing xylazine harm reduction due to:

• Rising overdose rates linked to “tranq” mixtures.
• Lack of approved reversal agents for xylazine toxicity.
• Growing addiction and treatment gaps for users.